1stOncology™: Cancer Intelligence Service – Page 11773 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Compugen Expands Intellectual Property Portfolio for COM701 With New European Composition of Matter Patent

On April 22, 2020 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported that The European Patent Office (EPO) has granted the Company a new patent for the composition of COM701 or backup antibodies for the treatment of cancer (Press release, Compugen, APR 22, 2020, View Source [SID1234556513]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

EPO Patent No. 3295951, titled "Anti-PVRIG Antibodies and Methods of Use," covers the composition of matter for COM701 and backup antibodies including any anti-PVRIG antibody having the binding fragments of COM701 or backup antibodies for the treatment of cancer.

The patent is expected to expire in Europe no earlier than February 2036.

About COM701

COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, and blocks the interaction with its ligand, PVRL2. TIGIT, discovered by Compugen’s computational discovery platform in 2009, and PVRIG constitute parallel immune checkpoint pathways that counteract DNAM, a costimulatory molecule on T cells and NK cells. Preclinical data suggest that the blockade of PVRIG induces a robust anti-tumor immune response and demonstrates synergistic activity when used in combination with inhibitors of TIGIT and/or PD-1. Currently, COM701 is being evaluated in a Phase 1 clinical study. Data from the ongoing study have shown that COM701 is well-tolerated and demonstrated preliminary signs of anti-tumor activity in a heavily pretreated patient population.

Luminex Corporation First Quarter Earnings Release Rescheduled for May 4, 2020

On April 22, 2020 Luminex Corporation (NASDAQ: LMNX) reported that it plans to report results for the first quarter ended March 31, 2020 on Monday, May 4, 2020 (Press release, Luminex, APR 22, 2020, View Source [SID1234556512]). A press release announcing the results is scheduled for release after the close of trading on that date.

Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2020 on May 4, 2020, at 5:00 p.m. Eastern Time.

The conference call will be webcast live and may be accessed at Luminex Corporation’s website at View Source Simply log on to the website, go to the About Luminex section and access the Investor Relations link. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the ‘replay’ link.

Invitation to Presentation of Immunovia’s Interim Report January – March 2020 on April 28, 2020

On April 22, 2020 Immunovia reported that invites to a teleconference (in English) for investors, analysts and media on Tuesday, April 28th, 2020 at 16:30 CET (Press release, Immunovia, APR 22, 2020, View Source;march-2020-on-april-28-2020-301045422.html [SID1234556511]). Immunovia will publish the company’s interim report on April 28th, 2020 at 16:00 CET.

Mats Grahn, CEO will present Immunovia and comment on the interim report for the period January – March 2020 followed by a Q&A session.

Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator:

Immunovia Webcast: https://channel.royalcast.com/webcast/immunovia/20200401_1/

There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (View Source) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

IntraOp® Announces First Patient Enrolled in Cosmopolitan Trial for Breast Cancer

On April 22, 2020 IntraOp Medical Corporation reported the first patient enrolled in the Cosmopolitan Trial: A randomized study of single treatment electron-beam intraoperative radiation therapy (IORT) delivered during surgery compared to external beam radiation therapy which is delivered over 3-4 weeks (Press release, IntraOp Medical, APR 22, 2020, View Source [SID1234556510]).

Breast cancer is the most frequent malignancy in women. For every 8 women, 1 will be inflicted with breast cancer during her lifetime. Many women suffer from side-effects related to their treatment. One of the most common side-effects of radiotherapy is fatigue, which, for 40% of patients, persists long after completing their treatment. Further, with rising healthcare costs, researchers are continuously investigating methods to de-escalate treatment not only to improve clinical results for their patients but also to reduce the socio-economic burden for such care.

Electron-beam IORT, which replaces 15 to 30 treatments of traditional radiotherapy, is the ultimate form of de-escalation for low risk breast cancer. Electron IORT may be particularly beneficial for patients who have an active lifestyle or travel long distances to receive their postoperative care. Fewer hospital visits not only reduces the burden on patients and their family but also hospital staff and resources—a topic at the forefront for all healthcare executives and government officials in the wake of the current COVID-19 pandemic.

The Cosmopolitan Trial is a multi-center trial led by Principal Investigator Prof. Jürgen Debus of Heidelberg University in Germany. The primary objective of the study is to demonstrate that electron IORT significantly increases the quality of life for patients; thereby reducing the socioeconomic burden for providing high quality care.

"Breast cancer remains one of the most common cancers inflicting women. The clinical evidence indicates that many breast cancer patients are being over treated; and we see a significant opportunity to employ electron IORT to de-escalate their treatment and significantly improve their quality of life while providing the same clinical effectiveness," said Prof. Jürgen Debus, Medical Director for the Department of Radiation Oncology at Heidelberg University.

"We are proud to sponsor the Cosmopolitan Trial as it strengthens the clinical evidence supporting the role of electron-beam IORT in treating breast cancer," said Derek T. DeScioli, CEO of IntraOp. "As the healthcare industry evolves to value-based care, we expect increased adoption of our technology. Every breast cancer patient should have the option to having their surgery and radiotherapy conveniently completed at the same time."

The American Journal of Managed Care® to Host Patient-Centered Oncology Care® 2020 Conference in Nashville

On April 22, 2020 The American Journal of Managed Care (AJMC), the leading multimedia peer-reviewed journal dedicated to issues in managed care, reported that the Patient-Centered Oncology Care (PCOC) 2020 conference will take place on Sept. 24 and 25 at the OMNI Nashville Hotel in Nashville, Tennessee (Press release, The American Journal of Managed Care, APR 22, 2020, View Source [SID1234556508]).

The dynamic program will be co-chaired by Joseph Alvarnas, M.D., editor-in-chief of AJMC’s Evidence-Based Oncology (EBO) and vice president of government affairs, senior medical director for employer strategy and associate clinical professor in the department of hematology and hematopoietic cell transplantation at City of Hope; and Kashyap Patel, M.D., associate editor of EBO, chief executive officer of Carolina Blood and Cancer Care Associates, vice president of the Community Oncology Alliance and trustee and clinical affairs chair for the Association of Community Cancer Centers.

"AJMC is proud to host our prestigious conference in Music City this fall," said Michael J. Hennessy Jr., president of MJH Life Sciences, parent company of AJMC. "At PCOC, attendees will be able to network with industry leaders and gain vital insight into the rapidly changing oncology care landscape."

During this two-day, patient-centered conference, featured speakers will engage in panel discussions on policy, precision health, chronic care management, biosimilars and the ways in which technology and telehealth are affecting care and value-based medicine. Attendees will have the opportunity to network with peers and engage with leaders from payer, community, academic and patient advocacy groups on critical issues in oncology value-based care.

"The Patient-Centered Oncology Care conference is a focus factory for disruptive ideas for how to create an innovative, sustainable, and patient-focused future for cancer care in this country. Key cancer stakeholders assemble in this forum to navigate the complexities of changing the ideal of value-based care into a practical reality," said Dr. Alvarnas.

Dr. Patel added, "We look forward defining value to promote quality and improve patient experience in cancer care at the PCOC conference."